Hypoglycaemia in Clinical Diabetes

REFERENCES 263Segel SA, Paramore DA, Cryer PE (2002). Hypoglycemia-Associated Autonomic Failure in advancedtype 2 diabetes. Diabetes 51: 724–33.Seltzer HS (1989). Drug-induced hypoglycemia. Endocrinology and Metabolism Clinics of NorthAmerica 18: 163–82.Shamoon H, Friedman A, Canton C, Zacharowicz L, Hu M, Rossetti L (1994). Increased epinephrineand skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. Journalof Clinical Investigation 93: 2562–71.Shorr RI, Ray WA, Daugherty JR, Griffin MR (1997). Incidence and risk factors for serious hypoglycemiain older persons using insulin or sulfonylureas. Archives of Internal Medicine 157: 1681–6.Spyer G, Hattersley A, Macdonald IA, Amiel S, MacLeod KM (2000). Hypoglycemic counterregulationat normal blood glucose concentrations in patients with well controlled type 2 diabetes. Lancet 356:1970–4.Stahl M, Berger W (1999). Higher incidence of severe hypoglycaemia leading to hospital admissionin type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. DiabeticMedicine 16: 586–90.Stephenson J, Fuller JH, on behalf of the EURODIAB IDDM Complications Study Group (1994).Microvascular and acute complications in IDDM patients: the EURODIAB IDDM complicationsstudy. Diabetologia 37: 278–85.Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC et al. (1999). Pharmacokinetics,pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. DiabetesTechnology and Therapeutics 1: 247–56.ter Braak EWMT, Appelman AMMF, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW(2000). Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia.Diabetes Care 23: 1467–71.ter Braak EWMT, Appelman AMMF, van Der Tweel I, Erkelens DW, van Haeften TW (2002). Thesulfonylurea glibenclamide induces impairment of glucagon and growth hormone responses duringmild insulin-induced hypoglycemia. Diabetes Care 25: 107–12.Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS (1994). Glibenclamide versus gliclazide intype 2 diabetes of the elderly. Diabetic Medicine 11: 974–80.The Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatmentof diabetes on the development and progression of long-term complications in insulin-dependentdiabetes mellitus. New England Journal of Medicine 329: 977–86.Thomson FJ, Masson EA, Leeming JT, Boulton AJM (1991). Lack of knowledge of symptoms ofhypoglycaemia by elderly diabetic patients. Age and Ageing 20: 404–6.Trovati M, Carta Q, Cavalot F, Vitali S, Banaudi C, Lucchina PG et al. (1984). Influence of physicaltraining on blood glucose control, glucose tolerance, insulin secretion and insulin action in noninsulin-dependentdiabetic patients. Diabetes Care 7: 416–20.UK Hypoglycaemia Study Group (2007). Risk of hypoglycaemia in types 1 and 2 diabetes: effects oftreatment modalities and their duration. Diabetologia 50: 1140–7.UK Prospective Diabetes Study (UKPDS) Group (1998a). Effect of intensive blood-glucose controlwith metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet352: 854–65.UK Prospective Diabetes Study (UKPDS) Group (1998b). Intensive blood-glucose control with sulphonylureasor insulin compared with conventional treatment and risk of complications in patients withtype 2 diabetes (UKPDS 33). Lancet 352: 837–52.United Kingdom Prospective Diabetes Study Group (1998c). A 6 year randomised controlled trialcomparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetesthat could not be controlled with diet therapy (UKPDS 24). Annals of Internal Medicine 128: 165–75.Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2001). No reactive hypoglycaemia in type 2 diabeticpatients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Medicine18: 144–9.